1. Pink Sheet

Pandemic Clinical Trials Need More Top-Down Control, Gottlieb Says

 
• By Anju Ghangurde

Ex-FDA commissioner offers British platform trials as examples of research done right, as he worries about studies that aren’t going to yield ‘definitive information’ crowding out trials that are more compelling and for more promising COVID-19 therapeutics.

FORMER FDA COMMISSIONER SCOTT GOTTLIEB SAYS CLINICAL TRIALS DURING A PANDEMIC MAY NEED MORE DIRECTED FLIGHT PATHS. • Source: Shutterstock

Scott Gottlieb wants regulators and policy-makers to control the clinical development environment better from a “top down approach” during a public health emergency.

Speaking to the recent Indegene Digital Summit 2020, the former US Food and Drug Administration commissioner lamented the lack of useful data that resulted from much of the clinical research conducted during the pandemic,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D